Lignosus Side Effects: What Are the Potential Risks?

Tiger milk mushroom, known scientifically as Lignosus rhinocerotis (or L. rhinocerus), has shown a clean safety profile in the research conducted so far, with no serious side effects reported in animal toxicity studies or the handful of human trials. That said, the total body of evidence remains small, and “no serious side effects observed” in a few studies is not the same as “proven safe for everyone.” Several theoretical risks and practical precautions are worth understanding before you start taking it.

What Animal Toxicity Testing Has Found

The most reassuring data on Lignosus safety comes from preclinical work in rats, where researchers pushed doses far beyond anything a human supplement would deliver. In one 28-day study, rats given up to 1,000 mg per kilogram of body weight daily of a related species (Lignosus tigris) showed no mortality, no signs of toxicity, no changes in body weight or organ weight, and normal blood chemistry throughout. The researchers concluded that the no-observed-adverse-effect level was above 1,000 mg/kg, meaning even the highest dose tested caused no detectable harm.¹

A longer study extended this observation dramatically. Rats given 1,000 mg/kg daily of L. rhinocerus sclerotial powder for 180 days showed no adverse effects on body weight, blood work, organ weight, or tissue structure under microscopic examination. The same research team also found that 100 mg/kg daily for seven to eight weeks did not affect rat fertility or cause birth defects in offspring.² A separate sub-acute study confirmed that the same dose range left kidney and liver function markers undisturbed.³

To put those numbers in context, a 1,000 mg/kg dose in a rat is many times larger, proportionally, than anything a person would take. Most Lignosus supplements marketed for humans suggest somewhere in the range of a few hundred milligrams per day total, not per kilogram. So the animal data provides a wide margin of safety at typical supplement doses.

No Evidence of DNA Damage

A separate concern with any substance you consume regularly is whether it could damage DNA, which is the first step toward causing cancer. Lignosus has been put through standard mutagenicity testing, and the results have been reassuring. The sclerotial powder did not cause gene mutations at concentrations up to 5,000 micrograms per plate in bacterial assays, whether or not a metabolic activation system was present.² Testing of the mushroom’s mycelium told a similar story: no mutagenicity was detected in any tested concentration, and no significant increase in chromosome damage was seen in animals given up to 2,000 mg/kg. Normal red blood cell production was also unaffected at that dose.⁴

These findings cover the standard battery of genotoxicity screens that regulators typically want to see for food or supplement ingredients. Passing them does not guarantee long-term safety in humans over decades, but it does clear a meaningful hurdle.

What Human Studies Have Reported

Human data on Lignosus side effects is limited, which is probably the most important thing to acknowledge. The few trials that exist are small, and the supplement industry moves faster than clinical research does.

An open-label study of tiger milk mushroom supplementation in people with respiratory complaints tracked changes in lung function, immunity, and inflammation markers over the supplementation period. Participants showed significant improvements in lung function and drops in inflammatory markers, and the study did not report treatment-related adverse effects.⁵ That study, however, was open-label, meaning there was no placebo group and neither participants nor researchers were blinded. This design is useful for spotting obvious problems but not ideal for detecting subtle side effects that might otherwise be attributed to other causes.

Stronger evidence comes from a randomized controlled trial in breast cancer patients in remission. This study compared a standardized Lignosus extract (TM02®) against a control group and specifically assessed safety. The result was straightforward: no significant differences in side effects between the two groups.⁶ For a population that is already immunologically vulnerable, this is a meaningful safety signal. But a single trial in one patient population still leaves open questions about other groups and longer durations of use.

Allergic Reactions and Fungal Cross-Reactivity

One risk that applies broadly to edible mushroom products is allergic reaction, particularly in people who are already sensitive to molds. Research on fungal cross-reactivity has established that foods derived from fungi, including edible mushrooms, can trigger allergic responses in people with existing mold allergies through a mechanism called fungus-food allergy syndrome.⁷ The proteins responsible for the allergic response in mushrooms often share structural similarities with proteins in airborne mold species.

A case study documented this overlap clearly: a patient with oral allergy syndrome had a positive skin prick test to raw mushroom and to four types of molds. Lab analysis revealed that antibodies directed against proteins in the raw mushroom cross-reacted with proteins in three of those mold species. Interestingly, the problem proteins were absent in cooked mushrooms, suggesting that heat processing breaks down the allergenic structures.⁸

No specific case reports of allergic reaction to Lignosus supplements appear in the published literature. But since Lignosus is a fungal product that shares many of the same protein families as other edible mushrooms, the cross-reactivity risk is plausible. If you have diagnosed mold allergies or have experienced oral allergy symptoms when eating mushrooms, this is worth discussing with an allergist before supplementing. How a particular Lignosus product is processed, whether the raw material has been heat-treated or undergone extensive extraction, could also matter for allergenicity, though no study has tested this directly with Lignosus.

Pregnancy, Lactation, and Other Gaps in the Evidence

The human trial that assessed respiratory health explicitly excluded pregnant and lactating women from participation, along with anyone taking antimicrobial or antiviral medications or who had undergone major surgery within the preceding six months.⁵ These exclusions were not based on evidence that Lignosus is harmful in those groups. They are standard practice in early-stage supplement trials, designed to keep the study population simple and reduce confounding variables. But the practical consequence is that no human safety data exists for these populations.

The rat fertility and teratogenicity data mentioned earlier is somewhat reassuring. At 100 mg/kg daily, the mushroom did not impair fertility or cause developmental abnormalities in rat offspring.² But animal reproductive studies do not always predict what happens in human pregnancy, and the standard advice for any supplement without direct human safety data in pregnancy is to avoid it unless a healthcare provider specifically recommends otherwise.

Children represent another evidence gap. None of the published trials enrolled pediatric participants, so any use in children is essentially uncharted territory from a formal research standpoint. The same goes for people with autoimmune conditions, organ transplant recipients on immunosuppressive drugs, and anyone on chronic medication for serious illness. In each case, the issue is not that problems have been documented but rather that nobody has looked.

Immune Stimulation as a Theoretical Concern

Much of the interest in Lignosus centers on its ability to modulate the immune system. The open-label respiratory study found that supplementation roughly doubled a key immune marker (secretory IgA) and reduced inflammatory signaling molecules by more than half.⁵ Lab studies have separately shown that extracts from the mushroom can activate certain immune pathways, including ones involved in killing abnormal cells.⁹

For a healthy person, a modest boost in immune readiness sounds appealing. But immune stimulation is not universally beneficial. In autoimmune diseases like lupus, rheumatoid arthritis, or multiple sclerosis, the immune system is already overactive and attacking the body’s own tissues. Adding a supplement that further stimulates immune function could theoretically worsen flares or disease activity. No study has tested Lignosus in people with autoimmune conditions, so the risk is speculative, but immunologists generally recommend caution with immune-stimulating supplements in that population.

A similar caution applies to anyone taking immunosuppressive medications after an organ transplant or for conditions like inflammatory bowel disease. These drugs are carefully dosed to keep the immune system in check, and a supplement that pushes immune activity in the opposite direction could, in theory, interfere with that balance. The beta-glucan polysaccharides that are among the most bioactive compounds in Lignosus are well-established immune activators across many mushroom species, so this concern is not unique to Lignosus but applies to it as fully as it does to reishi, turkey tail, or shiitake extracts.

Why the Form of the Product Matters

Not all Lignosus supplements contain the same material, and this has real implications for what side effects are even plausible. The mushroom can be commercially prepared from three distinct parts: the sclerotium (the dense underground mass that has been used in traditional medicine for generations), the fruit body, and the mycelium grown in bioreactor culture. An analysis of all three developmental stages found that they differ considerably in chemical makeup. The fruit body and sclerotium are rich in carbohydrates and fiber but low in fat, while the mycelium contains higher levels of potassium, phosphorus, B vitamins, and essential fatty acids.¹⁰

The sclerotium has been the focus of most safety testing because it is the part used in traditional Malaysian medicine, where indigenous communities have used it to treat coughs, asthma, and fatigue.¹¹ If a supplement uses mycelium biomass or exopolysaccharides harvested from culture broth instead, the safety data from sclerotium-based studies may not directly apply. Research on bioreactor-grown Lignosus biomass and exopolysaccharides has found that these preparations can differ in biological activity and toxicity thresholds depending on the extraction method used. Mycelial biomass obtained directly from dried fungal cultures and exopolysaccharides extracted through chemical processing showed different potency profiles in toxicity assays.

For you as a consumer, this means a few things. First, check which part of the mushroom your supplement contains. Most reputable brands specify whether they use sclerotium, mycelium, or a combination. Second, standardized extracts with a branded designation, like the TM02® used in the breast cancer trial, have been through at least some formal safety screening. Generic “tiger milk mushroom” powders of uncertain origin have not necessarily undergone the same evaluation. Third, the supplement industry in most countries operates with relatively light regulatory oversight compared to pharmaceuticals. There is no guarantee that what is on the label matches what is in the capsule unless the product has been independently tested.

Drug Interactions

No formal drug interaction studies have been published for Lignosus. This is a common gap with mushroom supplements and herbal products in general, and it means any discussion of interactions is extrapolation from what the mushroom does biologically rather than from direct evidence of a problem.

The most obvious area of concern is anticoagulant and antiplatelet medications. Some medicinal mushrooms have shown mild blood-thinning activity in laboratory settings, and while Lignosus has not been specifically tested for this effect, the polysaccharide fraction that dominates its bioactive profile belongs to a class of compounds that has been associated with mild anticoagulant activity in other fungi. If you take warfarin, heparin, or similar medications, err on the side of caution.

The immune-modulating properties discussed earlier also raise a flag for anyone on immunosuppressive therapy. Cyclosporine, tacrolimus, and similar drugs work by dampening specific arms of the immune system. A supplement that upregulates immune markers like IgA or shifts inflammatory cytokine levels could, at least in theory, work against what those drugs are trying to achieve. The breast cancer trial used a standardized extract alongside conventional treatment without apparent problems, but that study’s participants were not on immunosuppressive regimens.⁶

Digestive Side Effects

The most commonly discussed side effects of mushroom supplements in general are gastrointestinal: bloating, gas, loose stools, or mild stomach discomfort, particularly in the first days of use. These are typically attributed to the high polysaccharide and fiber content that characterizes most medicinal mushrooms, and Lignosus is no exception. Its sclerotium and fruit body are rich in carbohydrates and dietary fiber.¹⁰

None of the published trials on Lignosus specifically report gastrointestinal complaints as a documented side effect. But these trials enrolled healthy or mildly ill adults, used moderate doses, and ran for relatively short periods. Anecdotal reports from supplement users do occasionally mention mild digestive upset, which is consistent with how beta-glucan-rich supplements behave across the board. Starting at a lower dose and increasing gradually is a practical approach if you are sensitive to fiber or have irritable bowel symptoms.

How Lignosus Compares to the Broader Medicinal Mushroom Category

Lignosus sits in a family of medicinal mushrooms that share many of the same bioactive compounds, particularly beta-glucan polysaccharides. Its polysaccharide fractions contain protein-polysaccharide complexes alongside pure beta-glucan fractions, a profile common to other medicinal fungi.¹² What sets Lignosus apart in the safety conversation is that it has been through more formal toxicological evaluation than many of its peers. The combination of acute, sub-acute, sub-chronic (180-day), reproductive, and mutagenicity testing represents a fairly thorough preclinical package by supplement standards.

Where Lignosus falls behind is in the volume of human clinical data. Reishi and turkey tail, for instance, have been studied in many more human trials across a wider variety of health conditions. The consequence is that the known side-effect profile for those mushrooms is more detailed, including documented cases of liver toxicity with certain reishi preparations and mild gastrointestinal effects with turkey tail at higher doses. Whether Lignosus would show similar issues with wider use is an open question. The absence of reported side effects in a small number of trials is not the same as evidence that side effects do not occur. It just means no one has looked hard enough yet.